SG11201702185UA - PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS - Google Patents
PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTSInfo
- Publication number
- SG11201702185UA SG11201702185UA SG11201702185UA SG11201702185UA SG11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA SG 11201702185U A SG11201702185U A SG 11201702185UA
- Authority
- SG
- Singapore
- Prior art keywords
- intermediates
- processes
- preparation
- c5ar antagonists
- c5ar
- Prior art date
Links
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 title 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462057107P | 2014-09-29 | 2014-09-29 | |
PCT/US2015/052697 WO2016053890A1 (en) | 2014-09-29 | 2015-09-28 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201702185UA true SG11201702185UA (en) | 2017-04-27 |
Family
ID=55583729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201702185UA SG11201702185UA (en) | 2014-09-29 | 2015-09-28 | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
Country Status (19)
Country | Link |
---|---|
US (5) | US9745268B2 (pt) |
EP (2) | EP3200791B1 (pt) |
JP (1) | JP6898229B6 (pt) |
KR (2) | KR102593431B1 (pt) |
CN (2) | CN106999481B (pt) |
AU (2) | AU2015324111B2 (pt) |
BR (1) | BR112017006232B1 (pt) |
CA (2) | CA2960733C (pt) |
DK (1) | DK3200791T3 (pt) |
ES (2) | ES2926828T3 (pt) |
IL (1) | IL251061B (pt) |
MA (1) | MA52308A (pt) |
MX (2) | MX368492B (pt) |
NZ (2) | NZ767823A (pt) |
PL (1) | PL3200791T3 (pt) |
PT (1) | PT3200791T (pt) |
RU (1) | RU2712233C2 (pt) |
SG (1) | SG11201702185UA (pt) |
WO (1) | WO2016053890A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2381778T3 (pl) | 2008-12-22 | 2017-01-31 | Chemocentryx, Inc. | Antagoniści c5ar |
JP2013529647A (ja) * | 2010-06-24 | 2013-07-22 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト |
WO2016053890A1 (en) | 2014-09-29 | 2016-04-07 | Chemocentryx, Inc. | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
TWI791423B (zh) | 2016-01-14 | 2023-02-11 | 美商卡默森屈有限公司 | C3腎絲球病變之治療方法 |
US20190144389A1 (en) | 2017-10-30 | 2019-05-16 | Chemocentryx, Inc. | Deuterated compounds as immunomodulators |
CN112423752A (zh) | 2018-06-07 | 2021-02-26 | 凯莫森特里克斯股份有限公司 | C5a拮抗剂和ANCA相关性血管炎的剂量和疗效 |
EP4233850A3 (en) | 2018-11-30 | 2023-09-20 | ChemoCentryx, Inc. | Capsule formulations |
KR102207333B1 (ko) * | 2019-09-09 | 2021-01-27 | 성균관대학교산학협력단 | 4중 연속 고리 화합물의 신규한 제조방법 |
CA3155950A1 (en) | 2019-11-08 | 2021-05-14 | Chemocentryx, Inc. | Salt forms of a complement component c5a receptor |
IL292317A (en) | 2019-11-08 | 2022-06-01 | Chemocentryx Inc | Free base crystal form of complement component c5a receptor |
MX2022005406A (es) | 2019-11-08 | 2022-05-24 | Chemocentryx Inc | Forma amorfa de un receptor de componente c5a de complemento. |
WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
CN113957106B (zh) * | 2021-11-03 | 2024-04-19 | 暨明医药科技(苏州)有限公司 | 一种Avacopan及其中间体的制备方法 |
CN114262291B (zh) * | 2022-01-04 | 2023-05-19 | 重庆医科大学 | 一种阿伐可泮的合成方法 |
WO2023158722A2 (en) | 2022-02-16 | 2023-08-24 | Teva Pharmaceuticals International Gmbh | Processes for preparation of avacopan and intermediates thereof |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
WO2000012074A2 (en) | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
RU2197288C2 (ru) | 1999-08-03 | 2003-01-27 | Тверская медицинская академия | Способ лечения больных хроническим гломерулонефритом |
JP2003532726A (ja) | 2000-05-05 | 2003-11-05 | スミスクライン・ビーチャム・コーポレイション | 新規抗感染症薬 |
CN1231464C (zh) | 2000-08-10 | 2005-12-14 | 三菱制药株式会社 | 新型3-取代的脲衍生物及其药学应用 |
CA2422342C (en) | 2000-09-14 | 2009-12-08 | Mitsubishi Pharma Corporation | Novel amide derivatives and medicinal use thereof |
IL154993A0 (en) | 2000-09-29 | 2003-10-31 | Neurogen Corp | High affinity small molecule c5a receptor modulators |
SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
WO2003008827A1 (de) | 2001-07-19 | 2003-01-30 | Luk Lamellen Und Kupplungsbau Beteiligungs Kg | Übertragungsstrecke zum ansteuern einer kupplung |
ATE360441T1 (de) | 2001-08-17 | 2007-05-15 | Tanox Inc | Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen |
HUP0401900A3 (en) | 2001-09-21 | 2005-08-29 | Sanofi Aventis | 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates |
ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
EP1487796A4 (en) | 2002-03-28 | 2005-11-16 | Neurogen Corp | SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR |
JP2006508894A (ja) | 2002-03-28 | 2006-03-16 | ニューロジェン・コーポレーション | C5a受容体調節因子としての置換テトラヒドロイソキノリン |
JP2005530719A (ja) | 2002-03-29 | 2005-10-13 | ニューロジェン コーポレーション | 病原性炎症要素を有する状態の治療のための組み合わせ療法 |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
US7138420B2 (en) * | 2002-08-08 | 2006-11-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzimidazole compounds |
WO2004018460A1 (en) | 2002-08-21 | 2004-03-04 | Neurogen Corporation | Amino methyl imidazoles as c5a receptor modulators |
FR2846654A1 (fr) | 2002-11-05 | 2004-05-07 | Servier Lab | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2004043223A2 (en) | 2002-11-05 | 2004-05-27 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
ATE552253T1 (de) | 2002-11-08 | 2012-04-15 | Novartis Int Pharm Ltd | 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren |
AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
BRPI0410630A (pt) | 2003-06-19 | 2006-06-13 | Pfizer Prod Inc | antagonista de nk1 |
WO2005007087A2 (en) | 2003-07-03 | 2005-01-27 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
US8071624B2 (en) | 2004-06-24 | 2011-12-06 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
EP1621536A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
CN101163693B (zh) | 2005-02-18 | 2013-03-06 | 阿斯利康(瑞典)有限公司 | 抗菌哌啶衍生物 |
US7880004B2 (en) | 2005-09-15 | 2011-02-01 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US20070112015A1 (en) | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
DK1951663T3 (en) | 2005-11-24 | 2016-10-10 | Dompé Farm S P A | (r)-arylkylaminoderivater og farmaceutiske sammensætninger indeholdende dem |
SI2359834T1 (sl) | 2006-03-15 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa |
WO2008022060A2 (en) | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
WO2008053270A2 (en) | 2006-10-31 | 2008-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an egfr antagonist for the treatment of glomerolonephritis |
CA2695031A1 (en) | 2007-06-29 | 2009-01-08 | Prabhat Kumar | Novel substituted piperidones as hsp inducers |
CN102177152A (zh) | 2008-08-11 | 2011-09-07 | 哈佛大学校长及研究员协会 | 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途 |
EP2331561A4 (en) | 2008-09-03 | 2013-02-27 | Xenome Ltd | PEPTIDE CONJUGATE LIBRARIES AND METHODS OF MAKING SAME |
US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
LT2894165T (lt) | 2008-11-10 | 2023-03-10 | Alexion Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui |
US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
PL2381778T3 (pl) | 2008-12-22 | 2017-01-31 | Chemocentryx, Inc. | Antagoniści c5ar |
US20120252792A1 (en) | 2009-09-17 | 2012-10-04 | The Regents Of The University Of Michigan | Methods and compositions for modulating rho-mediated gene transcription |
JP2013529647A (ja) | 2010-06-24 | 2013-07-22 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト |
EA201590053A1 (ru) | 2012-06-20 | 2015-08-31 | Новартис Аг | Модуляторы пути системы комплемента и их применение |
US20160060351A1 (en) | 2013-05-08 | 2016-03-03 | Novo Nordisk A/S | Use of C5AR Antagonists |
WO2016053890A1 (en) | 2014-09-29 | 2016-04-07 | Chemocentryx, Inc. | PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS |
TWI791423B (zh) | 2016-01-14 | 2023-02-11 | 美商卡默森屈有限公司 | C3腎絲球病變之治療方法 |
NZ747259A (en) | 2016-04-04 | 2022-11-25 | Chemocentryx Inc | Soluble c5ar antagonists |
US20220257580A1 (en) | 2020-12-21 | 2022-08-18 | Chemocentryx, Inc. | Treatment of c3 glomerulopathy using a c5a inhibitor |
-
2015
- 2015-09-28 WO PCT/US2015/052697 patent/WO2016053890A1/en active Application Filing
- 2015-09-28 SG SG11201702185UA patent/SG11201702185UA/en unknown
- 2015-09-28 RU RU2017114960A patent/RU2712233C2/ru active
- 2015-09-28 CA CA2960733A patent/CA2960733C/en active Active
- 2015-09-28 CA CA3220371A patent/CA3220371A1/en active Pending
- 2015-09-28 AU AU2015324111A patent/AU2015324111B2/en active Active
- 2015-09-28 BR BR112017006232-1A patent/BR112017006232B1/pt active IP Right Grant
- 2015-09-28 PL PL15845610T patent/PL3200791T3/pl unknown
- 2015-09-28 EP EP15845610.3A patent/EP3200791B1/en active Active
- 2015-09-28 NZ NZ767823A patent/NZ767823A/en unknown
- 2015-09-28 CN CN201580052937.6A patent/CN106999481B/zh active Active
- 2015-09-28 ES ES20160995T patent/ES2926828T3/es active Active
- 2015-09-28 MX MX2017003789A patent/MX368492B/es active IP Right Grant
- 2015-09-28 KR KR1020177011789A patent/KR102593431B1/ko active IP Right Grant
- 2015-09-28 ES ES15845610T patent/ES2802428T3/es active Active
- 2015-09-28 EP EP20160995.5A patent/EP3682879B1/en active Active
- 2015-09-28 MA MA052308A patent/MA52308A/fr unknown
- 2015-09-28 NZ NZ730123A patent/NZ730123A/en unknown
- 2015-09-28 PT PT158456103T patent/PT3200791T/pt unknown
- 2015-09-28 JP JP2017516679A patent/JP6898229B6/ja active Active
- 2015-09-28 CN CN202110432100.1A patent/CN113121415A/zh active Pending
- 2015-09-28 DK DK15845610.3T patent/DK3200791T3/da active
- 2015-09-28 KR KR1020237035689A patent/KR20230149873A/ko active Application Filing
- 2015-09-28 US US14/867,669 patent/US9745268B2/en active Active
-
2017
- 2017-03-09 IL IL251061A patent/IL251061B/en active IP Right Grant
- 2017-03-23 MX MX2019011911A patent/MX2019011911A/es unknown
- 2017-07-25 US US15/659,468 patent/US10266492B2/en active Active
-
2019
- 2019-03-21 US US16/360,195 patent/US10532982B2/en active Active
- 2019-12-06 US US16/706,296 patent/US20200354320A1/en not_active Abandoned
-
2021
- 2021-06-22 AU AU2021204209A patent/AU2021204209B2/en active Active
-
2022
- 2022-02-08 US US17/667,289 patent/US11845729B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL251061A0 (en) | Processes and building materials in the preparation of c5ar antagonists | |
IL279606A (en) | Anti-TREM2 antibodies and methods of using them | |
HK1243102A1 (zh) | 抗cd79b抗體和使用方法 | |
IL250415B (en) | Antibodies against pd-l and methods of using them | |
HRP20181359T1 (hr) | Anti-jagged1 protutijela i postupci uporabe | |
IL251868A0 (en) | Anti-tim3 antibodies and methods of use | |
GB201421847D0 (en) | Dispensers and methods of use thereof | |
IL251165A0 (en) | Anti-il-1beta antibodies and methods of their use | |
IL247754A0 (en) | Antibodies against mcam and related methods of use | |
IL247315B (en) | Anti-acth antibodies and their uses | |
HK1250146A1 (zh) | 抗前-bcr拮抗劑和方法 | |
IL251286A0 (en) | Anti-pdgf-b antibodies and methods of use | |
ZA201604870B (en) | Recombinant microorganisms and methods of use thereof | |
HK1246288A1 (zh) | S1pr2拮抗劑及其用途 | |
IL247448A0 (en) | Peptides and methods of use | |
GB201509977D0 (en) | Dispensers and methods of use thereof | |
PL3229772T3 (pl) | 6-arylo-9-glikozylopuryny i ich zastosowanie | |
GB201404133D0 (en) | Garment and method of use thereof |